Search

Objectives: The therapeutic effect of acupuncture treatments (AT) on functional gastrointestinal disorders (FGIDs) is contentious. A meta‐analysis was conducted to assess the efficacy and safety of acupuncture for FGIDs. Methods: The Cochrane Library, EMBASE, PUBMED, Web of Science, Wanfang Database, China National Knowledge Infrastructure, and VIP Database were searched through December 31, 2019 with no language restrictions. Risk ratio (RR) with 95% confidence interval (CI) was calculated to determine the improvement in symptom severity after treatment. Results: A total of 61 randomized controlled trials (RCTs) on FGIDs were included. The pooled results illustrated the following: compared to pharmacotherapy (RR 1.13, 95% CI 1.09–1.17), placebo acupuncture (RR 1.69, 95% CI 1.37–2.08), no specific treatment (RR 1.86, 95% CI 1.31–2.62), and AT as an adjuvant intervention to other active treatments (RR 1.25, 95% CI 1.21–1.30), AT had more favorable improvements in symptom severity; sub‐group analysis results classified according to functional dyspepsia, irritable bowel syndrome, and functional constipation also supported this finding; and the incidence of adverse events was lower in AT than in other treatments (RR 0.75, 95% CI 0.56–0.99). Conclusions: This meta‐analysis found that AT was significantly associated with relief of FGIDs symptoms; however, the evidence level was moderate or low. Further data from rigorously designed and well powered RCTs are needed to verify the effectiveness and safety of AT as a FGIDs treatment. PROSPERO PROTOCOL NUMBER: CRD42020169508. [ABSTRACT FROM AUTHOR]

ABSTRACT The separation of rac-o-chloromandelic acid 1 with enantiopure aryloxypropylamine via diastereomeric salt formation was investigated. ( R)- o-chloromandelic acid ( R)- 1, a key intermediate for the antithrombotic agent clopidogrel, was obtained in 65% yield and 98% ee by Dutch resolution of rac- 1 with ( S)-2-hydroxyl-3-( p-chlorophenoxy) propylamine ( S)- 5 as resolving agent and ( S)-2-hydroxyl-3-( o-nitrophenoxy) propylamine ( S)- 4 as nucleation inhibitor. Chirality 24:1013-1017, 2012. © 2012 Wiley Periodicals, Inc. [ABSTRACT FROM AUTHOR]